Today: 4 February 2026
Subscribe
Browse Category

EPA:SAN.PA News 15 December 2025

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis (MS) medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one…
15 December 2025
·····

Stock Market Today

  • Shell Faces Pressure to Sustain Earnings Amid Falling Oil Prices in Q4 2025 Results
    February 4, 2026, 2:41 AM EST. Shell is set to report its Q4 and full-year 2025 results amid challenging market conditions. Despite a nearly 19% drop in Brent crude oil prices during 2025 and a slump below $60 per barrel, Shell's upstream production and liquefied natural gas output show resilience. However, earnings are expected to decline by about 20% year-on-year for the full year and approximately 10% for Q4, with anticipated losses in the chemicals segment and lower profits in energy trading. The oil giant's track record under CEO Wael Sawan-who has led Shell to beat earnings expectations in five of the last eight quarters-faces scrutiny, especially as the company balances reduced capital expenditure with aggressive share buybacks. Investors await clarity on Shell's ability to maintain capital returns and earnings growth amid sector volatility.
Go toTop